Announced Date: 2025-03-26 (March 26, 2025)
Asset Name: PH020 (BAY 3713372)
Licensor: Suzhou Puhe BioPharma (China)
Licensee (Buyer): Bayer（DE）
.
Asset Modality: Small Molecule, Oral
Asset Target: PRMT5 (protein arginine methyltransferase 5) inhibitor
Potential Indication: MTAP-deleted solid tumors
Current Stage: Phase I clinical trial, global
.
Scope of Authority:
Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor.
.
Payment Detail:
Undisclosed
.
Link:
Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
